Nanosequencing

Nanopore and other nanoscale DNA/RNA sequencing

71 companies 8 countries
N

NanoString Technologies

Seattle, United States

Life sciences company developing tools for gene expression analysis using nanoparticle-based molecular barcoding technology

NASDAQ: NSTG
L

Lux Capital

New York, United States

Venture capital firm investing in deep technology including nanotechnology

investor
E

Exosome Diagnostics

Waltham, United States

Exosome Diagnostics, founded in 2008 in Waltham, Massachusetts, emerged as a global leader in exosome-based liquid biopsy technology before being acquired by Bio-Techne Corporation. The company pioneered the use of exosomes—nanoscale extracellular vesicles (30-150 nm) naturally released by cells—as biomarkers for non-invasive disease detection and monitoring. Exosomes contain genetic material, proteins, and other molecular cargo that reflect the state of their cell of origin, making them valuable diagnostic tools for cancer and other diseases. Exosome Diagnostics developed sophisticated isolation and analysis technologies to capture these nanovesicles from bodily fluids and extract clinically relevant biomarkers, particularly RNA and DNA molecules. The company's flagship product, the ExoDx Prostate Test (IntelliScore), represents a breakthrough in prostate cancer detection, analyzing exosomal RNA from urine samples to help determine the need for prostate biopsy, thereby reducing unnecessary invasive procedures. This non-invasive approach leverages the natural biology of exosomes, which are shed into circulation and easily accessible through liquid biopsies. Exosome Diagnostics also developed comprehensive exosome isolation kits enabling researchers and clinicians to harness these nanosized vesicles for biomarker discovery and diagnostic applications. The company raised over $100 million in funding and established strategic partnerships with pharmaceutical companies and research institutions. The acquisition by Bio-Techne expanded the reach of exosome diagnostics technology within a larger life sciences organization. Exosome-based diagnostics represent a paradigm shift from traditional tissue biopsies to liquid biopsies, offering less invasive, repeatable testing that can track disease progression and treatment response. As precision medicine advances, exosome diagnostics continues to play a crucial role in enabling earlier disease detection, personalized treatment selection, and real-time monitoring, establishing exosomes as a transformative platform in nano-diagnostics and molecular medicine.

1

10x Genomics

Pleasanton, United States

10x Genomics, founded in 2012 in Pleasanton, California, has revolutionized biological research through innovative microfluidic and nanoscale technologies that enable unprecedented resolution in genomics analysis. The company went public on NASDAQ under ticker TXG, reflecting its status as a major player in the genomics technology sector with over 1,000 employees worldwide. 10x Genomics specializes in single-cell analysis and spatial biology, utilizing sophisticated nanofluidic systems that manipulate individual cells and molecules within nanoliter-scale droplets and nanofabricated chambers. The company's flagship Chromium platform employs microfluidic partitioning to isolate individual cells into nanoliter-sized gel beads in emulsion (GEMs), where each cell receives a unique molecular barcode. This nanotechnology-enabled approach allows researchers to analyze gene expression, immune repertoires, and epigenetic states at single-cell resolution, revealing cellular heterogeneity previously obscured in bulk tissue analysis. The Visium spatial genomics platform combines tissue imaging with transcriptomics, using nanoscale capture arrays to map gene expression while preserving spatial context within tissue sections. The newer Xenium in situ platform pushes resolution further, enabling subcellular visualization of hundreds of genes simultaneously through multiplexed in situ hybridization with nanoscale precision. These technologies rely on advanced nanofabrication techniques, precise microfluidic control, and molecular barcoding strategies that operate at nanometer scales. 10x Genomics products have become essential tools in cancer research, immunology, neuroscience, and developmental biology, enabling discoveries about cellular diversity, disease mechanisms, and therapeutic targets. The company's success demonstrates how nanotechnology enables transformative advances in life sciences, making previously impossible measurements routine. With continued innovation in nanofluidics, molecular barcoding, and imaging technologies, 10x Genomics continues to expand the frontiers of biological understanding at the single-cell and subcellular levels.

NASDAQ: TXG
T

Twist Bioscience

South San Francisco, United States

Twist Bioscience, founded in 2013 in South San Francisco, California, has revolutionized DNA synthesis through its innovative silicon-based nanoscale manufacturing platform. Trading on NASDAQ under ticker TWST, the company employs 500-1000 people and represents a convergence of semiconductor nanotechnology and synthetic biology. Twist's proprietary synthesis platform miniaturizes traditional DNA synthesis chemistry onto silicon chips using semiconductor photolithography and nanofabrication techniques, enabling massively parallel synthesis of oligonucleotides in nanoscale wells. This breakthrough reduces reagent consumption by over 1000-fold compared to conventional column-based synthesis while dramatically increasing throughput and reducing costs. The silicon-based approach allows Twist to synthesize millions of distinct DNA sequences simultaneously on a single chip, with each synthesis occurring in nanoliter or picoliter reaction volumes. The company's core products include custom synthetic genes, gene fragments, oligonucleotide pools, and next-generation sequencing libraries used in drug discovery, agricultural biotechnology, industrial chemicals production, and academic research. Twist has pioneered applications in DNA data storage, leveraging the massive information density of DNA molecules to archive digital data at nanoscale dimensions, with potential to revolutionize long-term data storage. The platform enables rapid design-build-test cycles for synthetic biology applications, accelerating development of therapeutic antibodies, enzymes, and novel biomolecules. Twist's nanotechnology-enabled manufacturing approach addresses the growing demand for synthetic DNA across biotechnology sectors, supporting applications from CRISPR gene editing to vaccine development. The company's success demonstrates how semiconductor nanofabrication techniques can transform biological manufacturing, creating a scalable, high-precision platform for the programmable synthesis of genetic material. As synthetic biology continues to expand, Twist's nanomanufacturing capabilities position it as critical infrastructure for biotechnology innovation, enabling researchers and companies worldwide to access high-quality synthetic DNA quickly and affordably.

NASDAQ: TWST
O

Oxford Nanopore Technologies

Oxford, United Kingdom

Pioneer in nanopore DNA/RNA sequencing technology enabling real-time, long-read sequencing

LSE: ONT
P

Pacific Biosciences

Menlo Park, United States

Developer of single molecule real-time (SMRT) DNA sequencing technology

NASDAQ: PACB
I

Illumina

San Diego, United States

Global leader in DNA sequencing using nanoscale flow cell technology

NASDAQ: ILMN
N

NanoString Technologies

Seattle, United States

Developer of molecular barcoding technology for gene expression analysis

NASDAQ: NSTG public
P

Pacific Biosciences

Menlo Park, United States

Developer of SMRT sequencing using zero-mode waveguides

NASDAQ: PACB public
S

Singular Genomics

La Jolla, United States

Next-gen sequencing platform with nanoscale engineering

NASDAQ: OMIC public
N

Nabsys

Providence, United States

Developer of electronic genome mapping using nanochannels

Q

Quantum Biosystems

Tokyo, Japan

Single-molecule electrical sequencing technology

Q

Quantum-Si

Branford, United States

Single-molecule protein sequencing

NASDAQ: QSI public
I

Ionis Pharmaceuticals

Carlsbad, United States

Antisense oligonucleotide therapeutics for genetic diseases

NASDAQ: IONS public
E

Editas Medicine

Cambridge, United States

CRISPR-based medicines for genetic diseases including eye disorders

NASDAQ: EDIT public
D

DNA Script

Paris, France

Enzymatic DNA synthesis for on-demand oligo production

S

Standard BioTools

South San Francisco, United States

Microfluidics and mass cytometry for life science research

NASDAQ: LAB public
S

Symrise

Holzminden, Germany

Fragrances, flavors, and cosmetic ingredients

XETRA: SY1 public
E

Editas Medicine

Cambridge, United States

Genome editing company using CRISPR with lipid nanoparticle delivery systems

NASDAQ: EDIT public
I

Ionis Pharmaceuticals

Carlsbad, United States

Pioneer in antisense technology and RNA-targeted therapeutics

NASDAQ: IONS public
E

Exiqon

Vedbaek, Denmark

Locked nucleic acid technology for RNA research and diagnostics

A

Akadeum Life Sciences

Ann Arbor, United States

Microbubble technology for fast, gentle cell separation and enrichment

G

Guardant Health

Redwood City, United States

Liquid biopsy for cancer detection using circulating tumor DNA analysis

NASDAQ: GH public
G

GRAIL

Menlo Park, United States

Multi-cancer early detection using cell-free DNA and advanced sequencing

F

Foundation Medicine

Cambridge, United States

Comprehensive genomic profiling for cancer using advanced sequencing

T

Tempus

Chicago, United States

AI-driven precision medicine with genomic sequencing and diagnostics

N

Natera

Austin, United States

Cell-free DNA testing for prenatal screening and cancer detection

NASDAQ: NTRA public
I

Invitae

San Francisco, United States

Genetic testing company with comprehensive hereditary cancer panels

NASDAQ: NVTA public
M

Myriad Genetics

Salt Lake City, United States

Molecular diagnostics for hereditary cancer and prenatal screening

NASDAQ: MYGN public
C

Color Health

Burlingame, United States

Population-scale genetic testing and COVID-19 testing infrastructure

2

23andMe

Sunnyvale, United States

Consumer genetics company with health and ancestry DNA testing

NASDAQ: ME public
A

Ancestry

Lehi, United States

Family history and consumer DNA testing using advanced genotyping

B

BGI Genomics

Shenzhen, China

Genomics company with sequencing platforms and diagnostic services

SZSE: 300676 public
B

Berry Genomics

Beijing, China

Non-invasive prenatal testing and genetic diagnostics in China

SZSE: 000710 public
A

Annoroad Gene Technology

Beijing, China

Genomic sequencing services and bioinformatics solutions

B

Burning Rock Biotech

Guangzhou, China

Cancer genomics and liquid biopsy diagnostics company in China

NASDAQ: BNR public
S

Singlera Genomics

Shanghai, China

DNA methylation-based early cancer detection and liquid biopsy

M

MGI Tech

Shenzhen, China

DNA sequencing instruments and reagents using proprietary technology

SSE: 688114 public
T

Twist Bioscience

South San Francisco, United States

Silicon-based DNA synthesis platform for synthetic biology

NASDAQ: TWST public
N

Nautilus Biotechnology

Seattle, United States

Single-molecule proteomics platform for comprehensive protein analysis

NASDAQ: NAUT public
N

Nanopore Technologies

Oxford, United Kingdom

Nanopore-based DNA/RNA sequencing with portable devices

LSE: ONT public
E

Element Biosciences

San Diego, United States

Benchtop DNA sequencing with accuracy at scale

U

Ultima Genomics

Newark, United States

Ultra-low-cost genome sequencing technology

N

NanoCellect Biomedical

San Diego, United States

Microfluidic cell sorting for single-cell applications

R

RainDance Technologies (Bio-Rad)

Billerica, United States

Droplet digital PCR technology, acquired by Bio-Rad

P

Passage Bio

Philadelphia, United States

AAV gene therapies for CNS diseases with novel delivery

NASDAQ: PASG public
R

Regenxbio

Rockville, United States

AAV gene therapy using NAV Technology Platform

NASDAQ: RGNX public
S

Synthego

Redwood City, United States

CRISPR reagent supplier and genome engineering platform

C

Caribou Biosciences

Berkeley, United States

Clinical-stage CRISPR genome editing company developing transformative therapies

NASDAQ: CRBU public
A

Absci

Vancouver, United States

Generative AI drug creation company designing and validating novel biologic drugs

NASDAQ: ABSI public
M

Molecular Assemblies

San Diego, United States

Enzymatic DNA synthesis company enabling rapid gene synthesis and DNA data storage

C

Catalog Technologies

Boston, United States

DNA data storage company developing massive-scale digital data storage in DNA

C

Charles River Cell Solutions

Wilmington, United States

Contract research organization providing cell and gene therapy development services

NYSE: CRL public
R

Rocket Pharmaceuticals

Cranbury, United States

Gene therapy company developing treatments for rare childhood diseases

NASDAQ: RCKT public
N

Neurogene

New York, United States

Gene therapy company developing treatments for rare neurological diseases in children

NASDAQ: NGNE public
A

Abbott Laboratories

Abbott Park, United States

Global healthcare company with diagnostics and medical device solutions

NYSE: ABT public
Q

Qiagen

Hilden, Germany

Provider of sample to insight solutions for molecular diagnostics

NYSE: QGEN public
V

Veracyte

South San Francisco, United States

Genomic diagnostics company improving cancer diagnosis and treatment

NASDAQ: VCYT public
C

CareDx

Brisbane, United States

Precision medicine company focused on transplant diagnostics

NASDAQ: CDNA public
A

Adaptive Biotechnologies

Seattle, United States

Biotechnology company developing immune-driven medicine through sequencing

NASDAQ: ADPT public
B

Benson Hill

St. Louis, United States

Food tech company using CropOS platform to develop better plant genetics

NYSE: BHIL public
M

MyFitnessPal

Baltimore, United States

Nutrition tracking and fitness app with food database

T

TrainHeroic

Denver, United States

Strength and conditioning platform for coaches and athletes

T

Trace Genomics

San Francisco, United States

Soil microbiome testing and analytics

B

Biome Makers

West Sacramento, United States

Soil and plant microbiome intelligence

D

Dapper Labs

Vancouver, Canada

Sports NFTs and blockchain

G

Glint

Sunnyvale, United States

Employee engagement platform

NASDAQ: MSFT
N

Nava PBC

Washington, United States

Public benefit corporation for government technology

N

NanoString Technologies

Seattle, United States

Molecular barcode technology for gene expression analysis

NASDAQ: NSTG public
B

Bionano Genomics

San Diego, United States

Genome analysis tools using nanochannel technology